Bio-Techne Corporation Bio-Techne Corporation

Bio-Techne Corporation

TECH

Classifica tra le azioni #1874
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Prezzo delle azioni
$72.55
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$11.38B
Variazione (1 giorno)
0.03%
Variazione (1 anno)
17.27%
Paese
US
Scambia Bio-Techne Corporation (TECH)

Categoria

Healthcare
Margine operativo per Bio-Techne Corporation (TECH)
Margine operativo al October 2026 TTM: 20.73%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Bio-Techne Corporation, il margine operativo attuale (TTM) è 20.73%. Alla fine del 2024, il margine operativo era 17.83%.
Storico del margine operativo per Bio-Techne Corporation da 2000 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
2026 (TTM) 20.73% 147.37%
2025 8.38% -53.00%
2024 17.83% -32.21%
2023 26.30% -1.98%
2022 26.83% 67.06%
2021 16.06% 58.85%
2020 10.11% -42.52%
2019 17.59% -16.95%
2018 21.18% -2.08%
2017 21.63% -28.33%
2016 30.18% -7.17%
2015 32.51% -27.19%
2014 44.65% -12.49%
2013 51.02% -3.44%
2012 52.84% -6.03%
2011 56.23% -3.22%
2010 58.10% 1.72%
2009 57.12% 1.91%
2008 56.05% 0.90%
2007 55.55% 3.73%
2006 53.55% -2.14%
2005 54.72% 7.25%
2004 51.02% 9.25%
2003 46.70% 15.74%
2002 40.35% 1.61%
2001 39.71% 4.80%
2000 37.89% 0.00%
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
38.59% -98.14%
US
-149.01% -107.19%
US
25.57% -98.77%
AU
0.00% -
CH
28.81% -98.61%
NL
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.